During the Southeastern Educational Congress of Optometry (SECO) 2025 meeting held from February 27 to March 2, 2025, in ...

Generated fourth quarter and full-year 2024 net product sales of XDEMVY® of $66.4 million and $180.1 million, respectively, ...

Colorado Springs, Colorado - Colorado Springs, CO — Colorado Springs Eyecare is excited to announce the addition of ZEST ...

Animal Humane New Mexico has formed a new partnership with the 15/10 Foundation associated with the We Rate Dogs social media ...

In reality, most cleansing rituals have few health and safety benefits. So, instead of cleansing more, perhaps we should ...

Q4 2024 Earnings Call Transcript February 25, 2025 Tarsus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Reports Q4 revenue $66.4M, consensus $58.8M. “Tarsus’ demonstrated category-creating blueprint has established XDEMVY as one of the most ...

The National Rosacea Society has opened its applications for research funding as the grant program celebrates its 25th ...

It’s human nature to try to make sense of what they see, even if what they see doesn’t make sense yet. Combining this with ...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed ...